

April 7, 2023

Announcement on Changes of the Board of Directors, Audit & Supervisory Board Members and Corporate Officers

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara) announced that it decided changes of the Board of Directors, Audit & Supervisory Board Members and Corporate Officers at a meeting of the Board of Directors held today.

The appointments for candidates of the Board of Directors and Audit & Supervisory Board Members will be resolved at the 75th Annual Shareholders Meeting scheduled for late June 2023. The changes and appointments of the Board of Directors and Corporate Officers will be officially decided at a meeting of the Board of Directors to be held on the same day after the Annual Shareholders Meeting.

1. Changes of the position of the Board of Directors (scheduled for late June 2023):
Except for the following Board of Director, incumbent of the Board of Directors will be re-appointed.
 - Resigning Board of Director:
Board of Director Isao Ono, Executive Officer / Director, Corporate Research
*: After resigning, he will be appointed as a senior partner.
2. Changes of Members of Audit & Supervisory Board (scheduled for late June 2023):
Except for the following candidates of Members of Audit & Supervisory Board, the incumbent Members will be in term.
 - Hironobu Tanisaka (full-time) and Akiko Tanabe (outside) will be re-appointed.
3. Changes of Corporate Officers (scheduled for late June 2023):
Except for the following candidates of Corporate Officers, incumbent Corporate Officers will be re-appointed.
 - Promoting candidates of Corporate Officers
Corporate Executive Officers:
Akira Takada, Executive Director, CMC & Production
Satoshi Takahagi, Executive Director, Sales and Marketing, Primary Care Business Division
 - New candidate of Corporate Officer
Masayuki Tanigawa, Executive Director, Corporate Development & Strategy
 - Resigning Corporate Officer
Corporate Executive Officers:
Yukio Tani, Head of Corporate Communications, Sustainability Promotion Department
Shozo Matsuoka, Executive Director, Corporate Regulatory Compliance, Safety and Quality Assurance
Corporate Officers:
Katsuji Teranishi, Chief Officer, Sales and Marketing, Wholesales Management and Planning, Primary Care Business Division
Hiroshi Ichikawa, Senior Director, Medical External Affairs
*: After resigning, the above 4 persons will be appointed as a partner.

< Reference >

The followings are the appointments of the Board of Directors, Audit & Supervisory Board Members as well as Corporate Officers (scheduled for late June 2023).

*: Candidates of the Board of Directors, and Audit & Supervisory Board Members for subject to approval at the 75th Annual Shareholders Meeting

The Board of Directors:

- Gyo Sagara* President, Representative Director, and Chief Executive Officer
- Toshihiro Tsujinaka* Senior Executive Officer, Executive Director, Corporate Strategy & Planning
- Toichi Takino* Senior Executive Officer, Executive Director, Discovery & Research
- Kiyooki Idemitsu* Executive Officer, Executive Director, Clinical Development
- Masao Nomura* Outside Director
- Akiko Okuno* Outside Director
- Shusaku Nagae* Outside Director

Audit & Supervisory Board Members:

- Katsuyoshi Nishimura Audit & Supervisory Board Member (full-time)
- Hironobu Tanisaka* Audit & Supervisory Board Member (full-time)
- Yasuo Hishiyama Outside Audit & Supervisory Board Member
- Akiko Tanabe* Outside Audit & Supervisory Board Member

Corporate Officers:

- Satoshi Numata Corporate Executive Officer, Executive Director, Digital & IT Strategy
- Akira Takada Corporate Executive Officer, Executive Director, CMC & Production
- Satoshi Takahagi Corporate Executive Officer, Executive Director, Sales and Marketing, Primary Care Business Division
- Hiromu Habashita Corporate Officer, Deputy Executive Director, Discovery & Research
- Shinji Takai Corporate Officer, Head of Medical Affairs
- Masaki Ito Corporate Officer, Senior Director, Corporate Planning, Business Management Division, Business Management Department, Operating Officer / President, Ono Digital health Investment, GK.
- Tatsuya Okamaoto Corporate Officer, Division Director, Clinical Development, Oncology Clinical Development Division, NV Strategic Planning, Global Project Management, Oncology
- Masayuki Tanigawa Corporate Officer, Executive Director, Corporate Development & Strategy

Ono Pharmaceutical Co., Ltd.

Corporate Communications

public_relations@ono-pharma.com